资讯

Precision Medicine Online15 分钟

FoRx Therapeutics Begins First-in-Human Trials for PARG Inhibitor

The firm will explore FORX-428's activity in patients whose tumors harbor DNA damage repair mutations or mutations that cause high DNA replication stress.